Lower circulating endocannabinoid levels in children with autism spectrum disorder

The endocannabinoid system (ECS) is a major regulator of synaptic plasticity and neuromodulation. Alterations of the ECS have been demonstrated in several animal models of autism spectrum disorder (ASD). In some of these models, activating the ECS rescued the social deficits. Evidence for dysregulations of the ECS in human ASD are emerging, but comprehensive assessments and correlations with disease characteristics have not been reported yet.

Molecular Pharmacology of CB1 and CB2 Cannabinoid Receptors

Mutational analysis of the cannabinoid receptor will surely contribute to our base of knowledge, building increasingly accurate molecular models of cannabinoid receptors. The ability to tailor future cannabinoid ligands to the receptor will hinge on how well this receptor system is understood. This understanding will potentially yield useful synthetic/modified cannabinergic therapeutic drugs and will very probably serve as future treatment modalities for symptoms of drug withdrawal and addiction. One possibility, on the forefront of pharmacogenomics research, is to create compounds that may activate cannabinoid receptors when there is a loss of endogenous ligand activity or ligand recognition owing to a mutation of those genes encoding the cannabinoid receptors.

Striking lung cancer response to self administration of cannabidiol: A case report and literature review

In spite of new drugs, lung cancer is associated with a very poor prognosis. While targeted therapies are improving outcomes, it is not uncommon for many patients to have only a partial response, and relapse during follow-up. Thus, new drugs or reevaluation of existing therapies used to treat other non-malignant diseases (drug repurposing) are still needed. While this research both in vitro and in vivo is being carried out, it is important to be attentive to patients where the disease responds to treatments not considered standard in clinical practice. We report here a patient with adenocarcinoma of the lung who, after declining chemotherapy and radiotherapy, presented with tumour response following self-administration of cannabidiol, a non-psychoactive compound present in Cannabis sativa. Prior work has shown that cannabidiol may have anti-neoplastic properties and enhance the immune response to cancer. The data presented here indicate that cannabidiol might have led to a striking response in a patient with lung cancer.

FULL VERSION VIDEO: Jahan Marcu 2nd Meeting of Tennessee’s Medical Cannabis Task Force 10 26 2017

This is the FULL VERSION VIDEO of Jahan Marcu in the 2nd Meeting of Tennessee’s Medical Cannabis Task Force In Nashville 10 26 2017! On October 26th 2017, there were at least nine guests and Representative Jeremy Faison, R-Cosby, introduces the next guest, Jahan Marcu, PhD, PFC Director and Chief Scientific Officer representing Safe Access Now. Jahan Marcu gives his speech and presentation about Safe Access Now’s mission of ensuring safe and legal access to cannabis for medical and research purposes. Jahan Marcu gives his presentation and begins to take questions, plus much more!